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Hemangiosarcoma (HSA) is a malignant neoplasm derived 
from precursor vascular endothelial cells. HSA is an uncommon
neoplasm in domestic animals, being more common in dogs 
than in cats. For that reason the information that we have about 
feline HSA is poor. (Johannes, et al., 2007)
INTRODUCTION
Selection of Case: feline cases were selected on the basis of a 
histological diagnosis of HSA. 
Information obtained: data were collected from the medical 
records including age, breed, gender, tumor site, results of 
diagnostic test, treatment outcomes, surgical margins, survival 
time and cause of death. For continuous variables mean, 
standard deviation (SD), median and range were calculated. 
Statistical analysis: the association of postulate risk factors 
with survival time was determined in a series of Kaplan-Meier 
product limit survival analyses. A level of significance of value p 
<0,05 was used for all statistical tests. 
MATERIALS AND METHODS
• Most of the claims about feline HSA are controverted because all the information that we have about it comes from retrospective cases 
studies and published cases. There is discussion on some items. Release a prospective study could be warranted. 
• Anemia is a usual complication of HSA, caused by acute or chronic hemorrhage derived from primary or metastasis rupture and 
microangiopathic hemolytic disease. 
• Most of the biochemical alterations associated to HSA are caused by the tumor location, or by the hypotension derivated from 
hemorrhage caused by primary or metastasis rupture
CONCLUSIONS
RESULTS AND DISCUSSION
• Middle-aged to older animals (ages ranged from 7 to 17 years, mean was 11,42±2,91 and median was 12).
• No breed or sex predilection were observed.
• There are different types of HSA classified according to their location as cutaneous, subcutaneous, visceral, oral cavity and
conjunctival. There is no agreement on the frequency of each form. 
• There is no agreement about which are the most frequent cutaneous and subcutaneous HSA locations.
• Some studies and our own results support that the most frequent locations in visceral feline HSA are spleen, liver mesentery, small 
and large intestine (Clup, et al., 2010; Ogilvie and Moore, 2001, Scavelli, et al., 1985).
• Although right atrium is the third most common site of occurrence of HSA  in dogs, primary cardiac HSA in the cat has been poorly 
reported (Merlo, et al., 2002).
• Kraje et al. (1999) reported metastatic disease in animals with cutaneous and subcutaneous HSA, located in lung, lymph nodes, 
spleen, kidney and eyes. The locations of metastasis reported in our study were spleen, kidney and lung.
• Scavelli, et al. (1985) claims that 60% of the cats suffering from visceral HSA developed metastasis. Our results support that the most 
frequent metastasis sites in visceral HSA were: liver, small bowel, mesentery and colon. 
• The treatment of choice is the complete surgical extirpation of the neoplasm. Benefits of intravenous chemotherapy is unclear.
• Comparisons of median survival time based on age, gender, tumor site, margins and biochemical changes were not statistically 
significant (Figure I and III). Comparison of median survival times based on the presence of anemia instead of normal red blood 
cells count was statistically significant (value p= 0,03) (Figure II).
• Cutaneous HSA in cats may have had more aggressive and metastatic behavior than previously thought, because 
some cats in this study have developed recurrence, metastasis and comparing median survival time based on 
tumor site showed no statistically significant difference. 
• The visceral HSA diagnosis usually is delayed. It may be the reason why often those animals suffer from metastasis 
at the time of diagnosis. 
to perform 
additional 
test 
Diagnostic test Results
Hematology
Blood smear
Regenerative and non regenerative anemia.
Polychromatic and hypochromatic erythrocytes, Howell-Jolly 
bodies, anisocytosis, macrocytosis, microcytosis, poikilocytosis, 
schistocytes and erythroblasts –
Neutrophilic leukocytosis, neutrophilia, leukopenia with 
neutropenia, leukopenia and lymphopenia. 
Thrombocytosis and thrombocytopenia. 
Biochemistry
Hypoproteinemia, hipoalbuminemia, increased alanine 
aminotransferase (ALT), reduced and increased blood urea 
nitrogen (BUN), reduced and increased creatinine.
Increased citrate prothrombin time and activated partial 
thromboplastin time (cit-PT and cit-aPTT)
Thorax and abdominal 
radiography
Effect Mass
Pulmonary metastasis
Ascites and pulmonary edema
Abdominal ultrasonography
Masses and metastasis
Cytology Erythrocytes and exceptionally fusiform neoplastic cells. 
Histology
Blood-filled vascular spaces lined by neoplastic endothelial 
cells.
Immunohistochemistry
Maskers such as factor VIII-related antigen allow us 
differentiate non-well differentiated HSA from sarcomas and 
telangiectatic osteosarcomas.
Figure I. Kaplan-Meier median survival time for
cats with hemangiosarcoma.
Figure II. Kaplan-Meier median survival time data
comparing cats with normal red cells count (blue)
and with anemia (green).
Figure III: Kaplan-Meier median survival time 
data comparing cats with visceral (green), 
cutaneous (blue) and other location (yellow) HSA. 
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Table I- Diagnostic test and results to expect in animals with HSA
Characterize the biological behavior, treatment outcomes, 
hematological and biochemical changes, prognostic risk factors 
and survival times of feline HSA.
OBJECTIVES
